logo

For the Inventor, By the Inventor

Seoul, South Korea

Chong Kun Dang Pharmaceutical Corporation

Calculating rank
USPTO Granted Patents = 52

% Expired Patents = 26.9



Trademarks = 2

Forward Citations = 115

Loading Chart...
Loading Chart...

208 inventors (with patents filed for the assignee):

goldMedal Hyeseung Song (8 out of 8 patents)

silverMedal Jong Lae Lim (8 out of 9 patents)

bronzeMedal Yuntae Kim (7 out of 54 patents)

4.  Jung Taek Oh (7 out of 7 patents)

5.  Chang Sik Lee (6 out of 20 patents)

6.  Min Hyo Ki (5 out of 8 patents)

7.  Dohoon Kim (5 out of 31 patents)

8.  Jaekwang Lee (5 out of 5 patents)

9.  Daekwon Bae (5 out of 5 patents)

10.  ChangSik Lee (5 out of 5 patents)

11.  Hyunjin Michael Kim (5 out of 5 patents)

12.  Shin Jung Park (4 out of 4 patents)

13.  Younghue Han (4 out of 4 patents)

14.  Jaeki Min (4 out of 9 patents)

15.  Miseon Bae (4 out of 4 patents)


Core Competencies:
Histone Deacetylase Inhibitors
Cancer Treatments
Pharmaceutical Formulations
Gastritis Treatment
Gene Delivery
Naltrexone Compositions
Testosterone Undecanoate
Esomeprazole
Oxadiazole Derivatives
CETP Inhibitors
GPR119 Agonists
Erythropoietin Analogs

52 patents:

1. 12599613 - Composition comprising dutasteride (2026-04-14),
2. 12570646 - Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same (2026-03-10),
3. 12522601 - 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same (2026-01-13),
4. 12466827 - 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same (2025-11-11),
5. 12440484 - 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same (2025-10-14),
6. 12303543 - Composition for preventing or treating gastritis or peptic ulcer (2025-05-20),
7. 12251375 - Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate (2025-03-18),
8. 11958844 - 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same (2024-04-16),
9. 11918618 - Composition for preventing or treating gastritis or peptic ulcer (2024-03-05),
10. 11826460 - Stable pharmaceutical composition comprising testosterone undecanoate (2023-11-28),
11. 11813285 - Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate (2023-11-14),
12. 11759428 - Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate (2023-09-19),
13. 11571426 - Compositions for preventing or treating lupus (2023-02-07),
14. 11479612 - Anti-c-Met antibody and use thereof (2022-10-25),
15. 11420950 - Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same (2022-08-23),
Company Overview
Chong Kun Dang Pharmaceutical Corporation, based in Seoul, South Korea, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative treatments in areas such as cancer therapy, gastritis management, and gene delivery systems. Its core technologies include histone deacetylase inhibitors and formulations for various therapeutic applications, including naltrexone and testosterone undecanoate. Chong Kun Dang is committed to advancing healthcare solutions through research and development in the pharmaceutical sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

52 Patents

#121 in Seoul

#312 in South Korea

#13,581 in the World

Seoul, KR
Seoul, South Korea

Chong Kun Dang Pharmaceutical Corporation

Forward Citations = 115

208 inventors:

goldMedal Hyeseung Song (8 out of 8 patents)

silverMedal Jong Lae Lim (8 out of 9 patents)

bronzeMedal Yuntae Kim (7 out of 54 patents)

4.  Jung Taek Oh (7 out of 7 patents)

5.  Chang Sik Lee (6 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chong Kun Dang Pharmaceutical Corporation. Retrieved from https://idiyas.com/company/chong-kun-dang-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…